Dermorphin

Mu-Opioid Receptor Selectivity#

Dermorphin is a heptapeptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂) that binds the μ-opioid receptor (MOR) with sub-nanomolar affinity and near-complete selectivity over δ- and κ-opioid receptors. The defining structural feature is the D-alanine residue at position 2 — a non-standard D-amino acid that locks the peptide into a bioactive conformation complementary to the MOR binding pocket and confers resistance to aminopeptidases that would otherwise destroy an all-L heptapeptide in seconds.

"The sequence of dermorphin includes a D-alanine residue in position 2, a unique feature among natural peptides that confers high affinity and enzymatic stability." — Montecucchi et al., Int J Peptide Protein Res, 1981

Substitution or removal of the D-Ala² residue abolishes activity entirely, which is the SAR finding that underpins every subsequent dermorphin analog program (DALDA, [Dmt¹]DALDA, glycodermorphins, cyclic hybrids).

Potency Relative to Morphine#

On a weight basis, dermorphin is roughly 30–40× the potency of morphine at producing analgesia, and on the order of 1,000–2,000× morphine after intracerebroventricular administration in rodents. This is the single most important pharmacological fact about the compound — it is the reason microgram doses produce strong opioid effects, and the reason reconstitution error from a milligram-scale lyophilized vial is catastrophic.

"Dermorphin was 30 to 40 times more potent than morphine and highly selective for mu-opioid receptors in the guinea-pig ileum and mouse vas deferens assays." — Broccardo et al., British Journal of Pharmacology, 1981

Practical consequence: the therapeutic window for respiratory safety is narrow, not wide. Higher receptor potency does not translate to a better analgesia-to-respiratory-depression ratio. A milligram-scale dosing mistake from a 5 mg vial delivers something like 150 mg morphine-equivalent activity.

Gi/o Signalling Cascade#

Once MOR is engaged, the downstream pharmacology is the canonical opioid cascade:

• Gαi/o coupling → inhibition of adenylate cyclase → reduced intracellular cAMP
• GIRK potassium channel opening → membrane hyperpolarization of the post-synaptic neuron
• Voltage-gated calcium channel inhibition at the pre-synaptic terminal
• Suppression of neurotransmitter release (substance P, glutamate, CGRP) at spinal dorsal horn and supraspinal sites

The net effect is the suppression of nociceptive signal transmission at multiple levels of the pain neuraxis, plus the full constellation of off-target μ-opioid effects: respiratory depression in the brainstem, miosis at the Edinger-Westphal nucleus, euphoria in the mesolimbic system, constipation via enteric MOR, and HPG-axis suppression at the hypothalamus. There is no mechanism by which the MOR-mediated suppression of LH/FSH and elevation of prolactin can be separated from the analgesia — chronic dosing produces opioid-induced hypogonadism by the same receptor pharmacology that produces pain relief.

Pharmacokinetic Paradox: Short Plasma Half-Life, Long Analgesia#

The most counter-intuitive aspect of dermorphin's pharmacology is the mismatch between plasma clearance and duration of action.

"Native dermorphin had a plasma half-life of about 1.3 min in rats, indicating extremely rapid elimination unless modified or administered centrally." — Negri et al., British Journal of Pharmacology, 1998

Plasma t½ is ~1.3 minutes, yet central analgesia after intrathecal or intracerebroventricular administration persists for several hours. The reconciliation: dermorphin is rapidly cleared from the systemic compartment by renal and hepatic peptidases, but once it reaches the CSF / central compartment, slow receptor off-rate and limited redistribution out of the spinal compartment sustain the effect. This is why the only published human clinical data — a 1985 postoperative analgesia trial — used the intrathecal route, bypassing both blood-brain barrier penetration limits and rapid plasma clearance in a single move.

"In a randomized, double-blind postoperative pain trial, single intrathecal doses of dermorphin provided superior and longer-lasting analgesia compared to intrathecal morphine." — Keppel Hesselink & Schatman, Journal of Pain Research, 2018

For peripheral routes (IV, IM, SC), the native peptide crosses the BBB poorly relative to its receptor potency, which is why the analog literature shifted toward glycosylated derivatives like [Ser⁷-O-βGlc]dermorphin that recruit GLUT-1 transport across the endothelium.

Tolerance, Dependence, and HPG-Axis Suppression#

By mechanism, dermorphin produces the full MOR adaptation profile: receptor desensitization, β-arrestin recruitment, internalization, and the upregulation of compensatory cAMP signalling that underlies opioid tolerance and physical dependence. Cross-tolerance with morphine and other μ-agonists is expected. Early rodent work suggested tolerance and dependence may develop somewhat less aggressively than with morphine at equianalgesic doses, but this has never been confirmed in modern controlled studies and should not be relied on.

The physique-relevant consequence is opioid-induced hypogonadism. Chronic μ-agonism suppresses GnRH pulsatility at the hypothalamus, lowers LH and FSH, drops total and free testosterone in males, disrupts menstrual cycling in females, and elevates prolactin. Any subject combining a chronic opioid with an AAS protocol will have the suppression masked on-cycle and unmasked at PCT — the testosterone recovery curve that should follow nandrolone or testosterone cessation will stall, and the cause is frequently missed because the standard "low T after cycle" workup does not consider concurrent opioid exposure as a driver.

Common (most users)#

Dermorphin produces the full μ-opioid agonist side effect profile, amplified by its ~30–40× morphine potency on a weight basis. The "common" tier here is the baseline pharmacology, not a list of mild nuisances.

• Sedation and cognitive impairment — expected at any analgesic dose. No operation of vehicles or machinery during the active window. Subjects with a low opioid tolerance experience this more strongly.
• Nausea and vomiting — classical MOR effect, dose-dependent. Mitigated in clinical contexts with ondansetron; lower dosing reduces incidence.
• Pruritus — itching, particularly facial and truncal, is characteristic of intrathecal and parenteral opioid administration. Usually self-limiting; antihistamines blunt it.
• Constipation — peripheral MOR activity at gut μ-receptors. Persists even with brain-penetrant analogs. Hydration, fiber, and osmotic laxatives in protocols where repeat administration is documented.
• Miosis — pinpoint pupils; diagnostic of opioid exposure, not pathological in itself.
• Urinary retention — more common with neuraxial routes (intrathecal), less so with systemic administration.
• Euphoria — a "common" effect by mechanism, and the primary driver of abuse liability. Worth naming honestly rather than pretending it doesn't exist.

Uncommon (dose-dependent or individual)#

• Respiratory depression (mild-to-moderate) — reduced respiratory rate and tidal volume at supra-analgesic doses. The therapeutic window between analgesia and clinically meaningful respiratory depression is narrow for any high-potency μ-agonist, and dermorphin is no exception. Capnography or pulse oximetry is the only meaningful monitoring tool; subjective assessment is unreliable.
• Histamine release / injection-site reactions — less characterized than morphine but documented in animal work. Wheal, flare, and localized urticaria around injection sites.
• Orthostatic hypotension — opioid-mediated vasodilation and reduced sympathetic tone.
• Tolerance — develops with repeat administration on the same timescale as morphine. Cross-tolerance with other μ-agonists is expected.
• Opioid-induced endocrinopathy — chronic μ-agonism suppresses the HPG axis: LH and FSH fall, total testosterone drops, prolactin rises, morning cortisol can blunt. Bloodwork of interest where chronic exposure is documented: total/free testosterone, LH, FSH, prolactin, morning cortisol. Particularly relevant to subjects also running AAS protocols, where the suppression is invisible on-cycle and unmasked at PCT.
• Physical dependence — withdrawal syndrome on cessation after repeated dosing: rhinorrhea, lacrimation, myalgia, GI distress, anxiety, dysphoria, insomnia. Severity tracks dose and duration.

Rare but serious#

• Severe respiratory depression and apnea — the dominant lethal mechanism for any μ-agonist and the specific reason dermorphin is dangerous out of proportion to its peptide framing. Warning signs: respiratory rate <8/min, deep cyanosis, unresponsiveness, gurgling/agonal breathing. Naloxone reverses dermorphin-mediated respiratory depression in animal models, consistent with classical MOR pharmacology, and any laboratory handling this compound should have naloxone on hand as a baseline precondition.
• Fatal overdose from reconstitution error — the documented failure mode in the grey-market literature. A 5 mg vial of dermorphin contains roughly 150 mg of morphine-equivalent activity. Milligram-level mistakes in volumetric measurement from a lyophilized vial translate directly to fatal outcomes. Dilute reconstitution is the only defense.
• Serotonin syndrome — when combined with serotonergic agents (SSRIs, SNRIs, MAOIs, tramadol, MDMA). Mechanistically plausible with any opioid; reports exist for fentanyl, tapentadol, and meperidine. Hyperthermia, clonus, agitation, autonomic instability.
• Opioid-induced hyperalgesia — paradoxical pain sensitization with chronic exposure. Identified by worsening pain despite escalating doses.
• Addiction / opioid use disorder — high liability by mechanism. Rapid-onset, high-potency μ-agonists with euphoric effect have abuse potential equal to or exceeding morphine. There is no responsible recreational protocol.

Hard contraindications#

These are absolute. They do not get softened.

• Concurrent CNS depressants — benzodiazepines, alcohol, GHB, gabapentinoids, barbiturates, other opioids, and Z-drugs. Respiratory depression is additive and frequently lethal. This is how most opioid deaths happen.
• MAOI use — opioid + MAOI combinations produce serotonergic crises and hypertensive emergencies. Meperidine-class interactions are the precedent; assume dermorphin behaves similarly until proven otherwise.
• Untreated sleep apnea or severe COPD — baseline respiratory compromise plus a μ-agonist is a fatal combination at doses that would be unremarkable in a healthy subject.
• Active opioid use disorder or history of opioid dependence — high relapse and overdose risk.
• Pregnancy — opioid exposure produces neonatal abstinence syndrome, and dermorphin has zero reproductive safety data. Absolute contraindication.
• No naloxone available — handling any high-potency μ-agonist without naloxone access is unjustifiable.

Gender-specific and HPTA considerations#

No gender-specific dosing exists, and no gender-specific contraindications beyond pregnancy. The HPTA considerations matter for both sexes and are worth restating because they are routinely missed in opioid contexts:

• Males: chronic μ-agonism suppresses LH and total testosterone, raises prolactin, and produces opioid-induced hypogonadism — fatigue, low libido, ED, mood disturbance, loss of morning erections. In subjects running AAS, this hypogonadism is masked on-cycle and surfaces at PCT, where it can blunt recovery of endogenous production. SERM-based PCT does not address the opioid component; the opioid exposure itself has to stop.
• Females: menstrual irregularity, amenorrhea, infertility, reduced libido. Same prolactin elevation.
• Prolactin elevation is independently relevant to anyone running 19-nor compounds (nandrolone, trenbolone) where prolactin management is already part of the protocol — adding a μ-agonist on top compounds the problem.

Dermorphin is not a PCT-relevant compound in the AAS sense (it is not androgenic and does not directly suppress at the gonadal level), but chronic exposure produces functional hypogonadism via the hypothalamic-pituitary route. Subjects layering it onto AAS protocols are running two independent suppression mechanisms in parallel — worth understanding before that combination is initiated.